Medgenics (MDGN) Tops Q4 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- Tanker struck by projectile in Strait of Hormuz
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- AppLovin shares fall after court denies request against Unity
Medgenics Reports Fourth Quarter and Full Year 2015 Results and Advancement of NFC-1 Development Programs
February 17, 2016 8:00 AM ESTPHILADELPHIA, PA -- (Marketwired) -- 02/17/16 -- Medgenics, Inc. (NYSE MKT: MDGN)
Enrollment Initiated in Groundbreaking Non-interventional Phenotype/Genotype Study of mGluR Mutations in ADHD IND Clearance Received for 22Q11.2 Deletion SyndromeMedgenics, Inc. (NYSE MKT: MDGN) today reported financial results for the three and twelve months ended December 31, 2015, as well as several key business and clinical development program highlights.
"We have made tremendous progress over the past year in transitioning our strategy toward becoming a leading genomic... More
